eCOA is utilised for assessing a new drug’s efficacy and safety by gauging the feelings and functioning of participants in clinical trials. Credit: fizkes/Shutterstock.
Endpoint data solutions provider Clario has signed a definitive agreement for acquiring the electronic clinical outcomes assessments (eCOA) business of WCG.
This move is set to broaden Clario’s offerings in the neuroscience sector and its scientific ‘expertise’.
Along with paper evaluations, eCOAs are utilised for assessing a new drug’s efficacy and safety by gauging the feelings and functioning of participants in clinical trials.
WCG’s eCOA business claims to provide full-service clinical expertise, especially in the areas of psychiatry, neuropathic pain, rare diseases and neurology.
Both Clario and WCG’s customers can anticipate “no immediate changes” to current relationships or contracts.
The transaction is pending regulatory approvals and is subject to other customary closing conditions. Both companies will continue to work independently till the finalisation of the deal.
WCG CEO Sam Srivastava said: “WCG’s eCOA expertise and capabilities in subjective endpoints are a strategic and complementary fit with Clario’s endpoint solutions. This transaction allows WCG to focus on being a trusted partner in connecting sponsors and CROs with sites to accelerate trials through trial design, study review, site activation, and participant recruitment and retention.
“With a legacy of supporting clinical trials over more than five decades across 130 countries, we remain well-positioned to accelerate clinical research through our AI-enabled data, technology, and expertise, paving the way to bring life-saving therapies to patients, faster.”
In October 2024, Clario [announced a partnership](https://www.clinicaltrialsarena.com/news/clario-partners-with-pathai/) with AI-powered digital pathology solution provider PathAI to offer an integrated solution for improving gastrointestinal (GI) clinical trials’ efficiency.
Clario provides a comprehensive suite of evidence-generation solutions combining eCOA, respiratory endpoints, precision motion, cardiac solutions and medical imaging.
According to the company, its endpoint data solutions have been instrumental in over 26,000 trials across more than 100 nations.